
About Us
Meet the team behind Hemedex's innovative technology
Hemedex, Inc., was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology to quantify tissue perfusion (i.e., blood flow at the capillary level).
This technology addresses the need for real-time prognostic data in complex medical and surgical procedures.
These complex procedures often involve compromised vasculature, delayed ischemia, or other serious pathophysiology, resulting in high rates of morbidity, delayed recuperation, poor patient outcome, and higher overall costs.
Hemedex's patented technology can provide an early warning of impending tissue ischemia, help target appropriate therapies, and rapidly assess the effect of interventions on cerebral blood flow (CBF), thus providing clinicians with a powerful tool to enhance patient care.
All Hemedex products are FDA cleared.
Our Team
Experienced leadership in medical technology and neurocritical care


James L. Neal, J.D.
Chief Legal Counsel & Board Member

Deanna Bowman
Senior Director of Manufacturing



Wendi DeRienzo
Administrative Services Manager


Stefanie Cantin
Strategic Advisor, Product Development & Commercialization


Our Vision
To improve patient outcomes and reduce healthcare costs by providing insight for therapy
Our Mission
To elevate standards of care by delivering the most trusted and widely used tissue perfusion measurement devices available